Data presented here suggests HSP90 and p23 are involved in driving these cellular processes, further supporting these proteins as valid therapeutic targets in prostate cancer, and in the case of p23 as a putative prognostic indicator for metastatic progression in patients with lower grade tumours at diagnosis, an area of unmet clinical need. Here, PTGES3 is linked to prostate cancer.